Novo Nordisk Owner to Acquire Major Stake in Australian Life Sciences Firm
Novo Nordisk to Test Obesity Drugs Including Wegovy in Alcohol Use
Novo Nordisk (NVO) is planning to test whether its weight loss drugs, including semaglutide, marketed as Wegovy, can impact alcohol use in patients with liver disease, according to an update the company has posted on a federal registry of clinical trials.
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Patients using Novo Nordisk's (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on
Novo Nordisk A/S: Once-weekly and Once-monthly Mim8 Demonstrate Superior Reduction of Treated Bleeding Episodes Compared to On-demand and Prior Prophylaxis Treatment in People With Haemophilia A in the Frontier 2 Trial
One in Eight U.S. Adults Admits to GLP-1 Usage as Public Awareness Surges
Novo Nordisk A/S Purchases B Shares Worth DKK 5,428 Million From Novo Holdings A/S Under the 2024 Share Repurchase Programme
Weight-loss Drug Competition Heats Up. Is Wegovy in Trouble?
Novo Nordisk Slides While Moderna Pops: Tale of Two Pharma Stocks
Novo Nordisk Sales up 26% Driven by GLP-1s, Misses 11% on Wegovy
Novo Nordisk CEO on Weight Loss Drugs' 'Exciting Growth Story'
Trending Tickers: Shell, Apple, Novo Nordisk and Standard Chartered
Novo Nordisk GAAP EPADR of DKK 5.68, Revenue of DKK 65.35B; Updates FY24 Outlook
Novo Nordisk's Sales Increased by 22% in Danish Kroner and by 24% at Constant Exchange Rates to DKK 65.3 Billion in the First Three Months of 2024
Apple, Novo Nordisk Earnings, Jobless Claims: What to Watch
Eli Lilly Reports $2 Billion From Mounjaro, Zepbound in Q1 2024
Why These Analysts Are Bullish on Healthcare Stocks
Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024
Novo Nordisk A/S – Reduction of the Share Capital
Weight Loss Drugs and the Many Use Cases in Medical Treatments
Eli Lilly Obesity Therapy Succeeds in Late-stage Trials for Sleep Disorder
No Data